PMID- 30262672
OWN - NLM
STAT- MEDLINE
DCOM- 20191218
LR  - 20230813
IS  - 1555-905X (Electronic)
IS  - 1555-9041 (Print)
IS  - 1555-9041 (Linking)
VI  - 13
IP  - 10
DP  - 2018 Oct 8
TI  - Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk 
      among Patients on Hemodialysis.
PG  - 1534-1541
LID - 10.2215/CJN.02190218 [doi]
AB  - BACKGROUND AND OBJECTIVES: An association between proton pump inhibitor (PPI) use 
      and hip fracture risk has been described in the general population, where the 
      primary causative hypothesis focuses on impaired gastrointestinal calcium 
      absorption. The impact of acid suppressor use on hip fracture risk in a high-risk 
      subset, patients with ESKD requiring hemodialysis, is unknown and could help 
      further distinguish the reason for higher susceptibility among PPI users. DESIGN, 
      SETTING, PARTICIPANTS, & MEASUREMENTS: Using the US Renal Data System, we 
      identified all hip fracture events recorded between 2009 and 2014 among patients 
      dependent on hemodialysis. Eligible cases were matched on index date with ten 
      controls. We identified PPI and histamine-2 receptor antagonist use from Medicare 
      Part D claims covering 3 years before the index date and stratified according to 
      proportion of days covered by filled prescriptions. Using logistic regression 
      with multiple imputation for missing data, we estimated unadjusted and 
      multivariable-adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs). 
      RESULTS: We studied 4551 cases and 45,510 controls. Patients were older, more 
      likely to be female and white, and had shorter dialysis vintage; fewer were 
      obese. A larger proportion of patients had any prior PPI (70% versus 63%) or 
      histamine-2 receptor antagonist (25% versus 23%) use. Use of PPI was associated 
      with higher risk of hip fracture (adjusted OR, 1.19; 95% CI, 1.11 to 1.28). This 
      association remained within subgroups of low, moderate, and high PPI use, 
      yielding adjusted ORs of 1.16 (95% CI, 1.06 to 1.27), 1.21 (95% CI, 1.11 to 
      1.31), and 1.19 (95% CI, 1.08 to 1.31), respectively. CONCLUSIONS: Among patients 
      with ESKD on hemodialysis, PPIs and not histamine-2 receptor antagonists were 
      associated with hip fracture events.
CI  - Copyright (c) 2018 by the American Society of Nephrology.
FAU - Vangala, Chandan
AU  - Vangala C
AD  - Section of Nephrology, Baylor College of Medicine, Houston, Texas.
AD  - Division of Nephrology, Michael E. DeBakey VA Medical Center, Houston, Texas; 
      and.
FAU - Niu, Jingbo
AU  - Niu J
AD  - Section of Nephrology, Baylor College of Medicine, Houston, Texas.
FAU - Lenihan, Colin R
AU  - Lenihan CR
AD  - Division of Nephrology, Stanford University School of Medicine, Palo Alto, 
      California.
FAU - Mitch, William E
AU  - Mitch WE
AD  - Section of Nephrology, Baylor College of Medicine, Houston, Texas.
FAU - Navaneethan, Sankar D
AU  - Navaneethan SD
AD  - Section of Nephrology, Baylor College of Medicine, Houston, Texas.
AD  - Division of Nephrology, Michael E. DeBakey VA Medical Center, Houston, Texas; 
      and.
FAU - Winkelmayer, Wolfgang C
AU  - Winkelmayer WC
AUID- ORCID: 0000-0002-5272-425
AD  - Section of Nephrology, Baylor College of Medicine, Houston, Texas.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180927
PL  - United States
TA  - Clin J Am Soc Nephrol
JT  - Clinical journal of the American Society of Nephrology : CJASN
JID - 101271570
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
CIN - Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1458-1459. PMID: 30262671
MH  - Aged
MH  - Cross-Sectional Studies
MH  - Female
MH  - Hip Fractures/epidemiology/*etiology
MH  - Histamine H2 Antagonists/*adverse effects
MH  - Humans
MH  - Kidney Failure, Chronic/complications/*therapy
MH  - Male
MH  - Middle Aged
MH  - Proton Pump Inhibitors/*adverse effects
MH  - *Renal Dialysis
MH  - Retrospective Studies
MH  - Risk Assessment
PMC - PMC6218825
OTO - NOTNLM
OT  - Epidemiology and outcomes
OT  - Hip Fractures
OT  - Histamine
OT  - Histamine H2 Antagonists
OT  - Kidney Failure, Chronic
OT  - Logistic Models
OT  - Medicare Part D
OT  - Odds Ratio
OT  - Proton Pump Inhibitors
OT  - USRDS
OT  - case-control
OT  - drug safety
OT  - end-stage renal disease
OT  - obesity
OT  - renal dialysis
EDAT- 2018/09/29 06:00
MHDA- 2019/12/19 06:00
PMCR- 2019/10/08
CRDT- 2018/09/29 06:00
PHST- 2018/02/17 00:00 [received]
PHST- 2018/07/18 00:00 [accepted]
PHST- 2018/09/29 06:00 [pubmed]
PHST- 2019/12/19 06:00 [medline]
PHST- 2018/09/29 06:00 [entrez]
PHST- 2019/10/08 00:00 [pmc-release]
AID - 01277230-201810000-00014 [pii]
AID - 02190218 [pii]
AID - 10.2215/CJN.02190218 [doi]
PST - ppublish
SO  - Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1534-1541. doi: 10.2215/CJN.02190218. 
      Epub 2018 Sep 27.